8-KCorporate ChangesExhibits & Filings

ELI LILLY & Co 8-K Report, Bylaw Amendment (Aug 30, 2017)

Filed August 30, 2017For Securities:LLY

Summary

Eli Lilly & Co. (LLY) filed an 8-K on August 29, 2017, detailing amendments to its corporate bylaws. The primary focus of these amendments is to establish a clear succession plan for the Chief Executive Officer (CEO) role in the event of the incumbent's sudden death or incapacity. These changes outline a specific order of executive leadership who would temporarily assume the CEO's duties and powers. This ensures business continuity and operational stability for the company during unforeseen leadership transitions. The updated bylaws specify that this temporary authority will remain in effect until a permanent successor is appointed by the Board of Directors or the original CEO is able to resume their duties. Investors should note that this proactive measure is a standard corporate governance practice aimed at mitigating risk.

Key Highlights

  • 1Amendments to Eli Lilly's corporate bylaws were approved by the Board of Directors on August 29, 2017.
  • 2The amendments establish a temporary succession plan for the Chief Executive Officer (CEO) role.
  • 3This plan is activated in cases of the incumbent CEO's sudden death or incapacity.
  • 4The bylaws define a specific order of executive officers who will temporarily assume CEO duties.
  • 5The temporary authority granted is contingent on the Board of Directors appointing a new CEO or the incumbent resuming duties.
  • 6The complete amended bylaws are filed as an exhibit to this 8-K filing (Exhibit 99.1).

Frequently Asked Questions

The main purpose of this 8-K filing is to report amendments made to Eli Lilly's corporate bylaws concerning the temporary succession of the Chief Executive Officer (CEO) in the event of incapacity or death.

The bylaws outline a specific order of succession: first, the President; if unavailable, then the Chief Financial Officer; then the executive officer who is President of Lilly USA; followed by executive officers in charge of principal business units in descending order of revenue; and finally, the executive officer who is President of Lilly Research Laboratories; and if all are unavailable, the General Counsel.

The temporary authority will last only until the Board of Directors appoints a new Chief Executive Officer or determines that the incumbent CEO is able to resume their office.

No, this filing does not indicate any immediate leadership changes. It is a proactive governance measure to ensure continuity in case of future unforeseen events affecting the CEO's ability to perform their duties.